Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Parental and Medical Classification of Neurodevelopment in Children Born Preterm.
Pediatrics
January 2025
Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Background And Objectives: The likelihood and severity of neurodevelopmental impairment (NDI) affects critical health care decisions. NDI definitions were developed without parental perspectives. We investigated the agreement between parental vs medical classification of NDI among children born preterm.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Background: Few interventions have demonstrated efficacy for increasing diversity in Alzheimer's disease (AD) clinical research and fewer still have targeted disadvantaged neighborhoods specifically. As part of a larger study to test recruitment strategies into the UC Irvine Consent-to-Contact Registry (C2C), we qualitatively assessed experiences of conducting community-based outreach throughout disadvantaged neighborhoods in Orange County, California.
Method: We are conducting an interrupted time series design to test recruitment interventions, stratified by Area Deprivation Index (ADI), a validated measure of neighborhood disadvantage.
Background: With African Americans having two to three times the prevalence of Alzheimer's disease (AD) as compared to white Americans, a critical challenge for reducing health disparities is overcoming long-standing barriers to recruiting African Americans into aging and brain health research. Here, we describe strategies that we have found successful for recruiting over 500 older African Americans from Greater Newark, New Jersey, into brain health and AD research studies.
Method: (1).
Background: We have previously reported the neuroprotective effects of fosgonimeton in amyloid-β (Aβ)-driven preclinical models of Alzheimer's disease (AD). Fosgonimeton is an investigational small-molecule positive modulator of the neurotrophic hepatocyte growth factor (HGF) system, currently under investigation for mild-to-moderate AD (LIFT-AD; NCT04488419). Given the recent approvals of Aβ-targeting monoclonal antibodies (Aβ-mAbs) for the treatment of AD, and growing recognition that combination therapies may improve treatment outcomes, we sought to investigate the preclinical activity of fosgonimeton in the presence of Aβ-mAbs.
View Article and Find Full Text PDFBackground: Accumulating evidence highlights impairment of autophagy as a key pathological feature of neurodegenerative diseases including Alzheimer's disease (AD). Autophagy is a highly dynamic, lysosome-based degradation process that promotes the clearance of degenerative factors to maintain cellular functions, preserve metabolic integrity, and ensure survival. Impaired autophagic function leads to the abnormal accumulation of autophagic vesicles (i.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!